ArticleBiomedicines2021
Characterization of the Gut Microbiota in Individuals with Overweight or Obesity during a Real-World Weight Loss Dietary Program: A Focus on the Bacteroides 2 Enterotype.
Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 29 citations in OpenAlex.
- Intestinal Microbiome, Fecal Fermentation Profile, and Health Indices in HIV-Positive Men Versus Normal Controls Without HIV.Nutrients · 2026Article
- A Review on the Molecular Dynamics of EnterotypeInternational journal of molecular sciences · 2026Review
- Article
- Nutritional Status in Obesity: A Comprehensive Narrative Review of Dysbiosis, Micronutrient Deficiencies and the Effects of Probiotics/Synbiotics.Medicina (Kaunas, Lithuania) · 2026Review
- The Gut-Brain Axis in Obesity: Mechanisms, Development, and Therapeutic Perspectives.Current nutrition reports · 2026Review
- Gut microbiome and obesity care: Bridging dietary, surgical, and pharmacological interventions.Cell reports. Medicine · 2026Review
- Gut Microbial Composition, Oxidative Stress, and Immunity in Metabolic Disease: Toward Personalized Interventions.Antioxidants (Basel, Switzerland) · 2026Review
- Altered gut microbiota and serum metabolite profiles characterize postmenopausal bone loss: insights into the gut-bone axis.Frontiers in microbiology · 2026Article
- Bacterial clusters are associated with the risk of severe disease progression in inflammatory bowel disease irrespective of conventional disease categories.Microbiome research reports · 2026Article
- Prominent mediatory role of gut microbiome in the effect of lifestyle on host metabolic phenotypes.Gut microbes · 2025Article
- Review
- Obesity-induced cofilin1 pathway dysregulation: Possible molecular links between neuroinflammation, cognitive decline, and Alzheimer's disease biomarkers.IBRO neuroscience reports · 2025Article
- Gut Microbiota Enterotype as a Predictor of Sarcopenia in the Japanese Elderly Population.Nutrients · 2025Article
- Pathophysiological Links Between Inflammatory Bowel Disease and Cardiovascular Disease: The Role of Dysbiosis and Emerging Biomarkers.Biomedicines · 2025Review
- Parabacteroides as a promising target for disease intervention: current stage and pending issues.NPJ biofilms and microbiomes · 2025Review
- Is Deuterium Sequestering by Reactive Carbon Atoms an Important Mechanism to Reduce Deuterium Content in Biological Water?FASEB bioAdvances · 2025Review
- Colonization byFrontiers in immunology · 2025Article
- Leveraging human microbiomes for disease prediction and treatment.Trends in pharmacological sciences · 2025Article
- Review
- Obesity as Inducer of Cognitive Function Decline via Dysbiosis of Gut Microbiota in Rats.Brain sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDietary intervention is a cornerstone of weight loss therapies. In obesity, a dysbiotic gut microbiota (GM) is characterized by high levels of Bacteroides lineages and low diversity. We examined the GM composition changes, including the Bacteroides 2 enterotype (Bact2), in a real-world weight loss study in subjects following a high-protein hypocaloric diet with or without a live microorganisms (LMP) supplement.
method263 volunteers were part of this real-world weight loss program. The first phase was a high-protein low-carbohydrate calorie restriction diet with or without LMP supplements. Fecal samples were obtained at baseline and after 10% weight loss for 163 subjects. Metagenomic profiling was obtained by shotgun sequencing.
resultsAt baseline, the Bact2 enterotype was more prevalent in subjects with aggravated obesity and metabolic alterations. After weight loss, diversity increased and Bact2 prevalence decreased in subjects with lower GM diversity at baseline, notably in LMP consumers. Significant increases in
conclusionsBaseline microbiome composition is associated with differential changes in GM diversity and Bact2 enterotype prevalence after weight loss. Examining these signatures could drive future personalized nutrition efforts towards more favorable microbiome compositions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.